Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy Cataplexy

• Axsome Therapeutics reported that the U.S. FDA has accepted its New Drug Application for AXS-12 to treat cataplexy in patients with narcolepsy.
• The filing includes a target FDA decision date, with the agency indicating that no advisory committee meeting is planned for the review.

For Axsome Therapeutics, ticker NasdaqGM:AXSM, the FDA's acceptance of the AXS-12 NDA comes as the stock trades at $237.53. The company has seen strong share performance over longer horizons, with the stock up 32.9% year to date and 113.4% over the past year, while it is down 3.3% over the past week and 6.3% over the past month.

The AXS-12 filing points to a possible expansion into an orphan neurology indication that could add to Axsome Therapeutics' existing commercial portfolio if the drug is approved. With a target decision date now set and no advisory committee expected, investors have increased visibility on an upcoming regulatory milestone that could influence views on the stock's long term opportunity set.

Stay updated on the most important news stories for Axsome Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Axsome Therapeutics.

📰 Beyond the headline: 0 risks and 2 things going right for Axsome Therapeutics that every investor should see.

Quick Assessment

• ✅ Price vs Analyst Target: At US$237.53, Axsome Therapeutics trades about 15% below the consensus target of US$280.39.
• ✅ Simply Wall St Valuation: The stock is assessed as trading 74.9% below estimated fair value, flagging a wide valuation gap.
• ❌ Recent Momentum: The share price is down 6.3% over the past 30 days, even with the AXS-12 NDA now accepted.

There's only one way to know the right time to buy, sell or hold Axsome Therapeutics. Head to Simply Wall St's company report for the latest analysis of Axsome Therapeutics's Fair Value.

Key Considerations

• 📊 FDA acceptance of AXS-12 with a defined decision date adds a clear regulatory catalyst to the Axsome Therapeutics investment case.
• 📊 Watch the US$237.53 price against the US$280.39 analyst target, the 74.9% estimated discount to fair value, and any updates around the AXS-12 review timeline.
• ⚠️ The key risk is that regulatory outcomes for AXS-12 may differ from investor expectations, which could affect sentiment around Axsome Therapeutics despite no currently flagged risks in the data.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Axsome Therapeutics analysis. Alternatively, you can check out the community page for Axsome Therapeutics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com